Cargando…
Dissecting the mechanism of cytokine release induced by T-cell engagers highlights the contribution of neutrophils
T cell engagers represent a novel promising class of cancer-immunotherapies redirecting T cells to tumor cells and have some promising outcomes in the clinic. These molecules can be associated with a mode-of-action related risk of cytokine release syndrome (CRS) in patients. CRS is characterized by...
Autores principales: | Leclercq, Gabrielle, Servera, Llucia Alberti, Danilin, Sabrina, Challier, John, Steinhoff, Nathalie, Bossen, Claudia, Odermatt, Alex, Nicolini, Valeria, Umaña, Pablo, Klein, Christian, Bacac, Marina, Giusti, Anna-Maria, Schneider, Anneliese, Haegel, Hélène |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8855852/ https://www.ncbi.nlm.nih.gov/pubmed/35186442 http://dx.doi.org/10.1080/2162402X.2022.2039432 |
Ejemplares similares
-
Dissecting the Mechanisms Underlying the Cytokine Release Syndrome (CRS) Mediated by T-Cell Bispecific Antibodies
por: Leclercq-Cohen, Gabrielle, et al.
Publicado: (2023) -
JAK and mTOR inhibitors prevent cytokine release while retaining T cell bispecific antibody in vivo efficacy
por: Leclercq, Gabrielle, et al.
Publicado: (2022) -
Src/lck inhibitor dasatinib reversibly switches off cytokine release and T cell cytotoxicity following stimulation with T cell bispecific antibodies
por: Leclercq, Gabrielle, et al.
Publicado: (2021) -
Novel strategies for the mitigation of cytokine release syndrome induced by T cell engaging therapies with a focus on the use of kinase inhibitors
por: Leclercq, Gabrielle, et al.
Publicado: (2022) -
Two Distinct Pathways in Mice Generate Antinuclear Antigen-Reactive B Cell Repertoires
por: Faderl, Martin, et al.
Publicado: (2018)